{
    "clinical_study": {
        "@rank": "143027", 
        "arm_group": [
            {
                "arm_group_label": "Adult- V114 medium dose", 
                "arm_group_type": "Experimental", 
                "description": "Single vaccination on day 1."
            }, 
            {
                "arm_group_label": "Adult-V114 maximum dose", 
                "arm_group_type": "Experimental", 
                "description": "Single vaccination on day 1."
            }, 
            {
                "arm_group_label": "Infant-V114 medium dose", 
                "arm_group_type": "Experimental", 
                "description": "A 4-dose series at 2, 4, 6, and 12 to 15 months of age."
            }, 
            {
                "arm_group_label": "Infant-V114 high dose", 
                "arm_group_type": "Experimental", 
                "description": "A 4-dose series at 2, 4, 6, and 12 to 15 months of age."
            }, 
            {
                "arm_group_label": "Infant-V114 maximum dose", 
                "arm_group_type": "Experimental", 
                "description": "A 4-dose series at 2, 4, 6, and 12 to 15 months of age."
            }, 
            {
                "arm_group_label": "Infant-V114 low dose", 
                "arm_group_type": "Experimental", 
                "description": "A 4-dose series at 2, 4, 6, and 12 to 15 months of age."
            }, 
            {
                "arm_group_label": "Infant-V114 medium/high dose", 
                "arm_group_type": "Experimental", 
                "description": "A 4-dose series at 2, 4, 6, and 12 to 15 months of age."
            }, 
            {
                "arm_group_label": "Infant-Prevnar 13", 
                "arm_group_type": "Active Comparator", 
                "description": "A 4-dose series at 2, 4, 6, and 12 to 15 months of age."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess the effect of different dose levels of pneumococcal\n      polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and\n      infants."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Streptococcus Pneumoniae Infection", 
            "Pneumococcal Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pneumococcal Infections", 
                "Pneumonia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will consist of 2 stages. In stage 1, adult participants will be administered a\n      single dose of V114. After completion of a review of safety data from the adult cohort,\n      stage 2 of the study will enroll infants. Infants will receive a 4-dose schedule of either\n      an active comparator or 1 of 5 dose/adjuvant combinations of V114."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Infants -Healthy and able to attend all scheduled visits.\n\n        Adults:\n\n        -Highly unlikely to conceive from vaccination through to 6 weeks after administration of\n        the vaccine.\n\n        Exclusion Criteria:\n\n        Infants and Adults\n\n          -  Prior administration of any pneumococcal vaccine, any non-live vaccine within 14 days\n             or any live vaccine within 30 days\n\n          -  History of invasive pneumococcal disease\n\n          -  Known hypersensitivity to any vaccine component\n\n          -  Received systemic corticosteroids within 14 days of first vaccination\n\n          -  Known or suspected impairment of immune function\n\n          -  Febrile illness within 72 hours before vaccination\n\n          -  Received blood transfusion or blood products within 30 days. Infants\n\n          -  Mother has documented human immunodeficiency virus or is hepatitis B surface antigen\n             positive\n\n          -  Has asplenia or failure to thrive. Adults\n\n          -  Is breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "340", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037984", 
            "org_study_id": "V114-004"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Adult- V114 medium dose", 
                    "Adult-V114 maximum dose", 
                    "Infant-V114 medium dose", 
                    "Infant-V114 high dose", 
                    "Infant-V114 maximum dose", 
                    "Infant-V114 low dose", 
                    "Infant-V114 medium/high dose"
                ], 
                "description": "A 0.5-mL intramuscular dose", 
                "intervention_name": "V114", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Infant-Prevnar 13", 
                "description": "A 0.5-mL intramuscular dose", 
                "intervention_name": "Prevnar 13", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77555"
                    }, 
                    "name": "Call for Information (Investigational Site 0015)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murray", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84107"
                    }, 
                    "name": "Call for Information (Investigational Site 0006)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84109"
                    }, 
                    "name": "Call for Information (Investigational Site 0022)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Geometric mean concentration (GMC) of serotype-specific pneumococcal antibody at one month following the 3rd vaccination (infant participants)", 
            "safety_issue": "No", 
            "time_frame": "One month following the 3rd vaccination (approximately 7 months of age)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037984"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants achieving the serotype-specific threshold value of \u2265 0.35\u03bcg/mL at one month following the 3rd vaccination (infant participants)", 
                "safety_issue": "No", 
                "time_frame": "One month following the 3rd vaccination (approximately 7 months of age)."
            }, 
            {
                "measure": "Percentage of participants achieving the serotype-specific threshold value of \u2265 0.35\u03bcg/mL at one month following the 4th vaccination (infant participants)", 
                "safety_issue": "No", 
                "time_frame": "One month following the 4th vaccination (approximately 13 to 16 months of age)."
            }, 
            {
                "measure": "GMC of serotype-specific pneumococcal antibody at one month following the 4th vaccination (infant participants)", 
                "safety_issue": "No", 
                "time_frame": "One month following the 4th vaccination (approximately 13 to 16 months of age)."
            }, 
            {
                "measure": "GMC of serotype-specific pneumococcal antibody at one month following a single vaccination (adult participants)", 
                "safety_issue": "No", 
                "time_frame": "One month following a single vaccination."
            }, 
            {
                "measure": "Fold rise from baseline in GMCs of serotype-specific pneumococcal antibody at one month following a single vaccination (adult participants)", 
                "safety_issue": "No", 
                "time_frame": "Prevaccination and one month following a single vaccination."
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}